Document:

QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.29

    
    

 
 

WAKE FOREST UNIVERSITY
  
    LICENSE AGREEMENT    
    

        THIS AGREEMENT (the "Agreement"), effective October 6th, 1993, is made between WAKE FOREST UNIVERSITY, an educational institution organized under the laws
of the State of North Carolina having its principal offices at Winston-Salem, North Carolina 27109 ("Wake Forest"), and KINETIC CONCEPTS, INC., a Texas corporation with principal offices at
8023 Vantage Drive, San Antonio, Texas 78216 ("KCI"): 

        The
parties hereto agree as follows: 

	1.
	Definitions

        For
all purposes of this Agreement the following terms will have the meanings specified below: 

        1.1   KCI
will mean Kinetics Concepts, Inc. ("KCI"), and any Affiliate of Kinetic Concepts, Inc. 

        1.2   "Affiliate"
will mean an entity that directly or indirectly controls, is controlled by, or is under common control with, the specified entity. For purposes of this
Agreement, the direct or indirect ownership of more than 50% of the outstanding voting shares of an entity, the right to receive 50% or more of the profits or earnings of an entity, or the right to
control policy decisions of an entity, will be deemed to constitute control. 

        1.3   "The
Inventors" will mean Drs. Louis Argenta and Michael Morykwas, presently employees of Wake Forest. 

        1.4   "The
Invention" will mean a wound treatment technology described in the patent applications in Appendix A discovered and reduced to practice by The Inventors and
known by Wake Forest as Method and Apparatus to Enhance Closure and Health of Open Wounds. The Invention will also include all transferable technical
data, practices, plans, specifications, and other information or assistance with respect to the use of the invention. 

        1.5   The
term "Improvement" will mean any improved process, composition or product, as the case may be, for wound treatment by maintaining reduced pressure on a wound to
promote healing of the wound, made by either or both of The Inventors or other employees of Wake Forest working under the direction of The Inventors. 

        1.6   "Patent
Rights" will mean the pending United States and PCT patent applications filed on The Invention, and which are set forth in Appendix A attached hereto and
made a part hereof (hereinafter referred to as the "Patent Application(s)"), and United States and foreign patents issuing from said pending United States and PCT patent applications, and any patents
based upon any of said United States and PCT patents and applications (hereinafter referred to as the "Patent(s)"), and any applications claiming or entitled to claim foreign or domestic priority
including any continuations, continuations-in-part, divisions, reissues or extensions of any of the foregoing, together with any additional patents or applications which may be
subsequently added to Appendix A. 

        1.7   "Licensed
Products" will mean any products made or sold by KCI which: 

	a.
	are
covered by an Issued Claim; or

	b.
	are
manufactured by using a process which is covered by an Issued Claim; or

	c.
	the
use of which is covered by an Issued Claim. 

        1.8   "Licensed
Processes" will mean a method which is covered by an Issued Claim. 

        1.9   "Net Sales" will mean gross revenues from sales or leases of Licensed Products or Licensed Processes and Preissuance Products or Processes by KCI or any KCI Affiliate or
by a sublicensee to third parties less any discounts (quantity, trade, and cash), returns, freight and other transportation,

 

other delivery costs, use and withholding tax, sales tax, and value added tax. No deductions will be made for cost of collections. Licensed Products will be considered "sold" when delivered, billed
out, or invoiced, whichever comes first. If Preissuance Products or Processes or Licensed Products or Licensed Processes are used by KCI, Affiliates or sublicensees as premiums to promote, market,
sale, and/or lease products and or processes other than Preissuance Products or Processes or Licensed Products or Licensed Processes, such premiums will be deemed to have been sold at KCI's customary
sales price. Clinical trials or introductory free use of Licensed Products or Licensed Processes in the ordinary course of business will not be considered to be such a premium.

 

        1.10 "Zamierowski
Rights" will mean those U.S., PCT and/or foreign patent applications and patents listed in Appendix B, and any patents issuing from the pending
patent applications, or any related or corresponding U.S. or foreign applications or patents, as well as any continuations, continuations-in-part, divisions, reexaminations,
reissues, substitutes, renewals or extension of any of the foregoing patent applications or patents. 

        1.11 "FDA
Clearance" will mean the first date on which KCI receives FDA clearance to market in the U.S. Preissuance Products or Processes or Licensed Product or Process. 

        1.12 "Commercial
Launch" will mean the date on which KCI completes its first commercial (i.e., excluding market test sales) sale or lease in the U.S. of Preissuance Products
or Processes or Licensed Products or Processes. 

        1.13 "Market
Test" will mean a reasonably reliable market test conducted by KCI, or for KCI pursuant to KCI procedures, prior to Commercial Launch. 

        1.14 An
"Issued Claim" will mean either of the following: 

        A.    In
a country in which no patent coverage exists because (a) no patent application was yet or ever filed in such country, (b) no patent was yet or ever
issued in such country, or (c) any patent that has issued in such country does not have at least one unexpired claim under which the manufacture, sale or use of products or processes
(i) are covered by, (ii) are manufactured by using a process covered by, or (iii) the use of which is covered by at least one unexpired claim in such patent in such country, then
Issued Claim for such country will mean at least one unexpired claim in any U.S. patent within the Patent Rights. 

        B.    In
a country in which patent coverage exists and the manufacture, sale or use of products or processes in such country (i) are covered by, (ii) are
manufactured by using a process covered by, or (iii) the use of which is covered by at least one unexpired claim in a patent in such country within the Patent Rights, then Issued Claim for such
country will mean at least one unexpired claim in any patent within the Patent Rights in such country. 

        1.15 "Preissuance
Products or Processes" will mean products or processes (i) covered by, (ii) manufactured by using a process covered by, or (iii) the
use of which is covered by at least one pending claim contained in any patent application within the Patent Rights regardless of whether the patent application exists in the country of manufacture,
sale, or use. 

	2.
	Grant
of License 

        2.1   Wake
Forest hereby grants to KCI a worldwide right and license to make, have made, use, lease, sell, and sublicense the Preissuance Products and Licensed Products under
the Patent Rights, and to practice and sublicense the Preissuance Processes and Licensed Processes to the full end of the term(s) for which Patent Rights are granted unless sooner terminated as
hereinafter provided. 

        2.2   Wake
Forest hereby agrees that it has not granted and will not grant any other license under the Patent Rights anywhere in the world during the period of time commencing
with the effective date 

2

 

of
this Agreement and terminating with the expiration of Patent Rights unless the License under this Agreement is sooner terminated as hereinafter provided. 

        2.3   Wake
Forest reserves the right to make, have made, and use the Licensed Products and to practice and use the Licensed Processes for Wake Forest's own clinical, research,
and educational purposes. Under no circumstances will Wake Forest have the right to commercialize or to assist any other party to commercialize or exploit any portion of the Patent Rights during the
term of this Agreement. 

	3.
	Due
Diligence 

        3.1   KCI
will use reasonable best efforts consistent with industry practices for like products and processes to bring the commercial embodiment of the Invention to market
within a reasonable time after the effective date of this Agreement. To that end, KCI will develop and test a commercially viable prototype within one year of the effective date of this Agreement.
Within four months of FDA Clearance, KCI will use its reasonable best efforts to complete a Market Test. Within two months thereafter, KCI will use its reasonable best effort to complete Commercial
Launch. 

        3.2   If
Wake Forest believes that KCI has materially failed to meet the time schedule set forth in Section 3.1, and is not exercising reasonable best efforts as
provided herein, Wake Forest will serve KCI with notice of the same, specifying in reasonable detail the basis for its belief. KCI will have 90 days in which to respond. If the parties are
unable to resolve that dispute, it will be submitted to binding arbitration before a single arbitrator pursuant to the Commercial Arbitration Rules then in effect of the American Arbitration
Association. Evidentiary questions will be governed by the Federal Rules of Evidence. The arbitrator's judgment will be based on custom and practices in the industry and the monies, time and effort
devoted to the project among other pertinent factors. The arbitrator's award will be in writing and will set forth the findings and conclusions upon which the arbitrator based the award. The
arbitration will be held in Atlanta. KCI will reimburse Wake Forest for reasonable fees and expenses Wake Forest incurs in excess of $10,000 except that if the arbitrator finds that the position of
one party is unreasonable position, that party will reimburse all reasonable fees and costs of the other party. 

	4.
	Compensation 

        4.1   KCI
will pay Wake Forest a one-time, nonrefundable license issue fee of $[***] upon execution of this Agreement. Wake Forest will
credit one-half of the license fee against future royalties due to Wake Forest under Sections 4.2 or 4.3, provided however that such credit to KCI will be applied only up to
one-half of the amount due to Wake Forest in any single reporting period with any balance of such credit as well as any new credits being applied in successive reporting periods. The
credit for any single reporting period, however, will not exceed one-half of the amount due to Wake Forest in any single reporting period. 

        4.2.1 KCI
agrees to pay to Wake Forest as consideration for the rights, privileges, and license granted under this Agreement, an earned royalty of
[***]. 

        4.2.2 Sales
or leases of any Licensed Products or Processes will not be subject to more than one royalty, regardless of the number of patents included with the Patents
Rights applicable to such Licensed Products or Licensed Processes and Preissuance Products or Processes. 

        4.3.1 Upon first sale or lease of Preissuance Products or Processes or Licensed Products or Licensed Processes in the U.S. and for 5 years thereafter (the minimum
royalty period) KCI will pay Wake Forest a minimum royalty to maintain the exclusive License granted hereunder ("minimum royalty"), the amount of which will be established based on the Market Test.
KCI will make a reasonable estimate of the projected annual Net Sales and calculate projected earned royalties for each year of the minimum royalty period. The minimum royalty due each year of the
minimum royalty period will be [***]% of the projected earned loyalties for each such year of the minimum royalty

3

 

period. The minimum annual royalty will be non-refundable, but will be creditable against royalties otherwise due under this Agreement. If earned royalties do not equal or exceed the
minimum royalty and if KCI elects not to pay the minimum royalty during the minimum royalty period, the License will automatically convert to a nonexclusive License and the royalty reduction
provisions of Section 4.4 will no longer have any force or effect.

 

        4.3.2 Upon
first sale or lease of Licensed Products or Licensed Processes or Preissuance Products or Processes in the U.S., a floor royalty of $[***]
semi-annually ("floor royalty") is required to maintain the License in effect during the entire term of the License, and if KCI elects not to pay the floor royalty, Wake Forest will have
the option to terminate the License under this Agreement by providing written notice of termination to KCI. Payments of earned or minimum royalties will be credited against the floor royalty. 

        4.4.1 If
KCI is required to pay royalties or the like to a third party to acquire rights under additional patents of third parties and Wake Forest in good faith agrees that
such acquired rights are necessary in order to best commercialize The Invention, the parties will negotiate in good faith a royalty reduction in the earned royalty rate and minimum royalties, but not
floor royalties, set forth in Sections 4.2 and 4.3 of this Agreement. 

        4.4.2 KCI
secures an exclusive license or assignment of the Zamierowski Rights, the parties agree that the earned royalty set forth in Section 4.2 of this Agreement
will be reduced by [***] the amount of royalty payments actually paid to Zamierowski or by [***], whichever is less, or, as the case may be, the minimum
royalties as set forth in Section 4.3, but not floor royalties, will be reduced by [***] of royalty payments actually paid to Zamierowski or by
[***]% of the minimum royalty otherwise payable, whichever is less, during the period of the assignment or exclusive license of the Zamierowski Rights to KCI. This royalty
reduction is also subject to KCI supplying a copy to Wake Forest of all transfers, assignments or licenses of any of the Zamierowski Rights to KCI and any agreements with KCI relating to the
Zamierowski Rights, providing Wake Forest with proof of actual payments made to Zamierowski relating to the Zamierowski Rights, and permitting Wake Forest to audit KCI's records and books relating to
payments made by KCI to Zamierowski relative to the Zamierowski Rights. 

        4.4.3 Notwithstanding
any other provision of this Agreement, in no event will the earned royalty rate payable by KCI to Wake Forest under Section 4.2 of this
Agreement be less than [***]. 

        4.4.4 The
earned royalty rates provided herein are based on the assumption that KCI will have actual exclusivity in the market of wound treatment by maintaining reduced
pressure on a wound to promote healing of the wound. In the event that at least one other company is producing and selling, on a commercial basis, products or processes that are not covered by or do
not infringe the Patent Rights but are competitive to the Licensed Products and/or Licensed Processes, and are sufficient to account for at least a [***]% market share in the
market of wound treatment by maintaining reduced pressure on a wound to promote healing of the wound, the parties will negotiate in good faith to establish a revised earned royalty rate and minimum
royalty, but not floor royalty, given the actual market conditions then existing. Thereafter, if KCI regains actual exclusivity in the market of wound treatment by maintaining reduced pressure on a
wound to promote healing of the wound, the earned royalty rates and minimum royalty rates provided herein will return to their original levels. 

        4.5.1 KCI
agrees to provide to Wake Forest research support in the total amount of $[***], inclusive of all direct and indirect costs, over the first
three years from the execution of this Agreement for research at Wake Forest. The specific research to be supported will be established annually and will include projects of mutual interest negotiated
in good faith by the parties. The research program for the first year is attached as Appendix C. In the event the parties are unable to reach agreement on the research plan for the subsequent
years within 60 days of the second and third anniversaries of this Agreement, KCI will pay Wake Forest two-thirds of the amount remaining unpaid. 

4

 

        4.5.2 In
the event any developments or inventions that are not Improvements and are not within the Patent Rights arise during the course of the research performed under
Section 4.1.9, KCI will have an exclusive option to obtain a worldwide exclusive license to such developments and inventions on terms and conditions to be negotiated in good faith and that are
commercially reasonable under the circumstances provided, however, that KCI exercises its option within one year of the date that such development or invention is first disclosed to KCI. 

        4.5.3 The
provisions of Section 7 will apply to research performed under section 4.5.1. The principal investigator of such research projects will make periodic
written reports to KCI no less frequently than every six months describing the status, data and results of the research, as well as any developments or inventions. Unpatentable data and information
resulting from such research maybe used by KCI without restriction. 

        4.6   Royalties
will be reported to and paid to Wake Forest each 6 months as provided in Section 9. 

        4.7   KCI
will reimburse Wake Forest for all reasonable fees and costs incurred after the effective date of this Agreement to prepare, file, prosecute and maintain U.S., PCT
and foreign patent applications. Wake Forest will credit [***] of such reimbursement actually paid by KCI against future royalties due to Wake Forest under Sections 4.2 or 4.3,
provided however that any such credit to KCI will be applied only up to one-half of the amount due to Wake Forest in any single reporting period with any balance of such credit as well as
any new credits being applied in successive reporting periods. The credit for any single reporting period, however, will not exceed [***] of the amount due to Wake Forest in
any single reporting period. 

        4.8.1 KCI
will escrow earned or minimum royalties for sales or leases of Preissuance Products and Processes until one or more of the events of Section 4.8.2 occurs. 

        4.8.2 If
a U.S. patent under which the manufacture, sale or use of products or processes which (i) are covered by, (ii) are manufactured by using a process
covered by, or (iii) the use of which is covered by at least one claim within the Patent Rights issues within the time period of Section 10.1, KCI will immediately pay the escrowed
royalties for such products or processes to Wake Forest upon issuance of such patent. If no such U.S. patent within the Patent Rights issues within that time period then the escrowed royalties will be
returned to KCI after the expiration of such time period, provided that KCI gives written notice to Wake Forest of KCI's election to terminate the License under this Agreement, and such time period is
extended until written notice is provided to Wake Forest. If no U.S. patent within the Patent Rights has issued but in another country a patent has issued within the Patent Rights under which the
manufacture, sale or use of products or processes in such country (i) are covered by, (ii) are manufactured by using a process covered by, or (iii) the use of which is covered by
at least one claim, then the escrowed royalties attributable to sales in that country will be immediately paid to Wake Forest and future royalties from Net Sales in that country will be paid to Wake
Forest and will not be escrowed. 

        4.8.3 If
a U.S. patent under which the manufacture, sale or use of products or processes which (i) are covered by, (ii) are manufactured by using a process
covered by, or (iii) the use of which is covered by at least one claim within the Patent Rights issues within the time period of Section 10.1, royalties hereunder will be based solely on
Licensed Products and/or Licensed Processes. 

	5.
	Warranty 

        5.1   Wake
Forest warrants to its best knowledge and belief that it is the owner of all rights, title, and interest in the Patent Rights, free of any liens, encumbrances,
restrictions and other legal or equitable claims. Wake Forest warrants that it is not aware that the Patent Rights infringe the patent rights of any third party and that it is not aware that the
Invention is unpatentable. 

        5.2   All
property, whether tangible or intangible, which may be delivered hereunder, will be delivered on an "as is, where is" basis without any express or implied warranty.
Wake Forest makes no 

5

 

warranty
of merchantability or fitness for any particular purpose. Other than the obligations of Wake Forest set forth in this Agreement, WAKE FOREST MAKES NO OTHER WARRANTIES WHATSOEVER. WAKE FOREST
HEREBY DISCLAIMS ALL WARRANTIES WHETHER EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, ANY IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY IMPLIED WARRANTIES
ARISING FROM ANY COURSE OF DEALING, USAGE, OR TRADE PRACTICE. WAKE FOREST ASSUMES NO RESPONSIBILITY WITH RESPECT TO THE EXPLOITATION OR COMMERCIALIZATION OF THE PATENT RIGHTS OR THE MANUFACTURE, USE,
SALE, LEASE OR DISTRIBUTION OF ANY METHODS, PROCESSES, APPARATUS, DEVICES, SYSTEMS, PRODUCTS, ARTICLES, AND/OR APPLIANCES DERIVED FROM OR USING THE LICENSED PRODUCTS OR LICENSED PROCESSES BY KCI. WAKE
FOREST WILL NOT BE LIABLE FOR LOSS OF PROFITS, LOSS OF USE, OR ANY OTHER DIRECT, INCIDENTAL, CONSEQUENTIAL, OR EXEMPLARY DAMAGES. 

        5.3   Wake
Forest represents that it does not own or control any patents or other intellectual property rights that would dominate, interfere, or limit the rights granted
herein. In the event that, during the term of this Agreement, Wake Forest acquires such rights from the Inventor or other employees of Wake Forest working under the direction of The Inventors, KCI
will have an exclusive option to add such rights to the Patent Rights hereunder. 

	6.
	Future
Improvements 

        6.1   Until
the termination of the Agreement, Wake Forest will promptly provide KCI with information originated or acquired by Wake Forest relative to Improvements. Wake
Forest hereby grants to KCI the exclusive option to add to the Patent Rights any Improvement, subject to the terms and conditions of this Agreement. 

        6.2   In
the event that KCI makes or acquires any enhancement in or to The Invention or the Patent Rights, it will promptly disclose the same to Wake Forest, and at the option
of Wake Forest, KCI will grant Wake Forest a royalty-free non-exclusive right to practice said enhancement for Wake Forest's own clinical, research, and educational purposes.
Under no circumstances will Wake Forest have the right to commercialize or to assist any other party to commercialize or exploit any portion of the enhancement during the term of this Agreement. 

	7.
	Disclosure
Requirements 

        7.1   Wake
Forest and KCI will each select an employee who will act as its technical correspondent in transmitting technical information and in arranging for other assistance
necessary to fully exploit the Patent Rights. Each party will indicate promptly to the other in writing the name of its technical correspondent. The technical correspondents of Wake Forest and KCI
will cooperatively work out a practicable plan to keep each party informed about the other's current and planned activities relating to, the use, production, lease and sale of Licensed Products and
Licensed Processes. KCI will promptly provide Wake Forest with samples, drawings and related information for all prototype, test and/or commercial devices or products of KCI under the Patent Rights
and copies of all information, documents and data and samples and drawings of all devices under the Patent Rights prepared for or submitted to the FDA. 

        7.2   Wake
Forest's technical correspondent will be responsible for answering all reasonable technical inquiries received from KCI's technical correspondent relating to the
Invention, and will provide, to the extent requested, copies of pertinent technical information to KCI, including, to the extent applicable, test reports and other technical reports and manuals, lists
of ingredients and their proportions in compositions of matter and quality control procedures. 

6

 

        7.3   Wake
Forest will, on written notice, give to duly accredited representatives of KCI access to the inventor's laboratories, and other facilities, at reasonable times and
under reasonable conditions, for the purpose of acquiring technical information. 

        7.4   All
information exchanged by the technical correspondents will be subject to the provisions of Section 8 of this Agreement. 

	8.
	Confidentiality

        8.1   All
confidential information of either Wake Forest or KCI transmitted to the other party in conjunction with this Agreement, whether prior to or subsequent to the
execution of this Agreement, will be considered to be information which is confidential and proprietary when it is marked in writing as confidential. Such information will hereinafter be referred to
as "Confidential and Proprietary Information," and will be held in confidence, and will not be disclosed to third parties or used for any purpose other than to fulfill the obligations of this
Agreement without prior written consent of the providing party. Confidential and Proprietary information will not include information that: 

	(a)
	is
or becomes publicly available through no act or fault of the receiving party;

	(b)
	is
disclosed to the receiving party by a third party having the right to disclose it;

	(c)
	is
already known by the receiving party as shown by its prior written records provided the receiving party provides written notice to the providing party thereof promptly after
receiving the Confidential and Proprietary Information; or

	(d)
	is
required by law to be disclosed. 

        8.2   Except
as provided in Section 11.12, upon early termination of this License, each party will make no further use of the Confidential and Proprietary Information
and will promptly return to the other all written material which incorporates, or which is based on, or which derives from, or grows out of in whole or in part, any Confidential and Proprietary
Information provided by the other party except that each party may retain one copy of such information if required to do so by applicable governmental regulations. 

        8.3   All
obligations of confidentiality and non-disclosure set forth in this License will expire 5 years from the date of termination of the License under
this Agreement. 

	9.
	Records,
Reports, and Payments 

        9.1.1 KCI
will maintain and will require its sublicensees to maintain accurate records relating to the sale of the Licensed Products or Processes for 5 years
following the end of the calendar year to which they pertain. 

        9.1.2 The
books and records of KCI and its sublicensees relating to this Agreement, and the associated premises, will be open to inspection by Wake Forest at reasonable
intervals, and Wake Forest will be entitled, at its own expense, to request a firm of certified public accountants to inspect the books and records of KCI and its sublicensees and supply a certificate
with respect to the correctness of reports and payments due Wake Forest hereunder, and KCI and its sublicensees will grant such firm of certified public accountants all reasonable assistance necessary
thereto. The information obtained during such inspections will be considered Confidential and Proprietary Information and will be subject to Section 8 of this Agreement whether or not marked as
confidential. 

        9.2.1 KCI will render to Wake Forest semi-annual reports for the six month periods ending the last days of June and December each year. Reports will be submitted
before the last days of February and August of each year, and will show for the period:

 

	(a)
	All
Licensed Products and/or Preissuance Products distributed, leased and/or sold. 

7

 

	(b)
	Accounting
for all the Licensed Processes and/or Preissuance Processes distributed, leased, used or sold.

	(c)
	Deductions
applicable as provided in Section 1.9 or other credits provided in this Agreement.

	(d)
	Total
royalties due. 

KCI
will remit to Wake Forest with each such report the amount of royalty payments shown thereby to be due. If no sales or leases of the Licensed Products or Licensed Processes and/or Preissuance
Products or Processes were made during any calendar half year, KCI will provide to Wake Forest a statement to that effect. 

        9.2.2 KCI
will render to Wake Forest a similar report within 30 days after the termination of the License under this Agreement, covering the period from the last date
covered by the last preceding report to the date of termination. 

        9.3   Payments

        9.3.1 The initial minimum royalty payment will be made in accordance with Section 4.3 and will be due 60 days from the last day of the reporting period in
which initial sales or leases of Licensed Products or licensed Processes and/or Preissuance Products or Processes begin. The initial and final minimum royalties due will be prorated based on the
period of sales within the reporting period. Minimum or earned royalties, as the case may be, will be paid semiannually with the February and August reports required in Section 9.2.

 

        9.3.2 During
the minimum royalty period, KCI will pay the earned royalty or the minimum royalty due, whichever is greater. If the earned royalty is greater than the minimum
royalty due, KCI may credit the difference between the amount actually paid in earned royalties and the minimum royalty due against future minimum royalty payments. 

        9.3.3 Within
30 days following the termination of this Agreement, KCI will pay to Wake Forest the amount due to Wake Forest for the period from the last reporting
period covered by the last preceding payment to the date of termination. 

        9.3.4 Royalty
payments will be paid in United States dollars in Winston-Salem, North Carolina, or at such other place as Wake Forest may reasonably designate consistent with
the laws and regulations controlling in any foreign country. Any withholding taxes which KCI will be required by law to withhold on remittance of the royalty payments will be deducted from royalty
paid. KCI will furnish Wake Forest the original copies of all official receipts for such taxes. If any royalties hereunder are based on Net Sales converted from foreign currency, such conversion will
be made by using the exchange rate prevailing at a first-class foreign exchange bank on the last business day of the semiannual reporting period to which such royalty payments relate. 

	10.
	Patent
Prosecution 

        10.1 Wake
Forest and KCI agree to allow a 5-year period from the date of this Agreement for the issuance of a United States patent. This period may be extended
by KCI. 

        10.2 The
prosecution of the U.S., PCT and foreign patent applications and maintenance of all Patent Rights, if any, will be the primary responsibility of Wake Forest;
provided, however, that KCI will have reasonable opportunities to advise and will cooperate with Wake Forest in such prosecution and/or maintenance. Wake Forest will provide KCI's outside patent
counsel with copies of all official correspondence when received and copies of all proposed amendments or responses no less than 3 weeks prior to filing to permit KCI to comment thereon. 

8

 

        10.3 KCI
will designate those foreign countries, if any, in which KCI desires foreign patent coverage corresponding to U.S. patent coverage. KCI will pay all reasonable
costs and legal fees associated with the preparation and filing of such foreign patent applications, and such applications will be in Wake Forest's name. KCI will pay earned royalties to Wake Forest
in accordance with Section 4.2 on Licensed Products and/or Licensed Processes and/or Preissuance Products or Processes regardless of whether patent coverage exists in the country of sale,
manufacture or use. In the event KCI elects not to pursue foreign patent coverage in Canada, the European Patent Office (designating France, Germany, U.K., Austria, and Switzerland), Japan, Taiwan,
and Australia, then Wake Forest will be free to License a third party in any country in which patent coverage is not sought. 

        10.4 In
accordance with Section 4.7, KCI will reimburse Wake Forest upon presentation of itemized statements for all reasonable fees and costs incurred after the
effective date of this Agreement relating to the preparation, prosecution, and maintenance of U.S., PCT and foreign patent filings under the Patent Rights which are initiated by mutual agreement of
the parties. 

        10.5 Upon
any claim of any application of the licensed Patent Rights being canceled, abandoned, or disallowed by a final non-appealable or non appealed action of
the Patent Office having jurisdiction, or upon any claim of any patent of the Patent Rights being held invalid or unenforceable by a final non-appealable or a non-appealed
decision of any court or tribunal of competent judgment, such claim will be deemed to have expired, as of the date of final disallowance or holding of invalidity or non-enforceability. 

	11.
	Termination 

        11.1 If
no United States patent is issued during the period provided in Section 10.1, this Agreement may be terminated by KCI. 

        11.2 Unless
sooner canceled or terminated as herein provided, the License under this Agreement will continue for the full term of the last expiring Patent Rights. 

        11.3 If
KCI becomes bankrupt or insolvent, or files a petition in bankruptcy, or if the business of KCI is placed in the hands of a receiver, assignee or trustee for the
benefit of creditors, whether by the voluntary act of KCI or otherwise, the License under this Agreement will automatically terminate. 

        11.4 Should
KCI fail in its payment of any license fee, royalties or other payment to Wake Forest due in accordance with the terms of this Agreement, Wake Forest will have
the right to serve upon KCI, by certified mail at the address designated in Section 18, notice of its intention to terminate the License under this Agreement within 30 days after receipt
of said notice of termination Unless KCI will pay to Wake Forest, within the 30 day period, all such amounts due and payable. Upon the expiration of the 30 day period, if KCI will not
have paid all such royalties due and payable, the rights, privileges and license granted hereunder will thereupon immediately terminate. KCI will continue to be obligated to pay Wake Forest all
license fees, royalties and other payments due to Wake Forest at the time of termination. 

        11.5 Upon
any material breach or default of this Agreement by KCI, other than those occurrences set out in Sections 11.3 and 11.4, which will always take precedence in that
order over any material breach or default referred to in this paragraph, Wake Forest will have the right to terminate the License under this Agreement and the rights, privileges and license granted
hereunder by 90 days' notice by certified mail to KCI. Such termination will become effective unless KCI will have cured any such breach or default prior to the expiration of the 90 day
period from receipt of Wake Forest's notice of termination. 

        11.6 Alternatively,
should KCI be in breach or default as set forth above, and should Wake Forest be in a position where it could rightfully terminate the License under this
Agreement, then in its sole 

9

 

discretion,
Wake Forest may convert this exclusive license to a non-exclusive license upon giving notice of such decision to KCI. 

        11.7 KCI
will have the right to terminate the License under this Agreement with or without cause at any time on 6 months' notice by certified mail to Wake Forest. 

        11.8 Upon
termination of the license under this Agreement, in whole or part, for any reason or cause, the continuation of all existing sublicenses hereunder will become
subject to the election of Wake Forest as follows: Wake Forest may elect to succeed to all of the rights and obligations of KCI with respect to any or all such sublicenses or may elect to allow any or
all such sublicenses to terminate with the license to KCI under this Agreement. Any sublicense granted by KCI must contain provisions corresponding to this Section relative to termination and the
conditions of continuance of any sublicenses. 

        11.9 Upon
termination of the License under this Agreement for any reason, nothing herein will be construed to release either party from any obligation accrued prior to the
effective date of such termination. KCI may, however, after the effective date of such termination, sell all Licensed Products, and complete Licensed Products in the process of manufacture at the time
of such termination and sell or lease the same, provided that KCI will pay to Wake Forest the royalties thereon as required by Section 4 and will submit the reports required by Section 9
on the sales of Licensed Products. 

        11.10 Upon
termination of this License for any reason, the rights granted herein will immediately revert to Wake Forest. 

        11.11 If,
at any time during this Agreement, KCI directly or indirectly opposes or assists any third party to oppose the grant of any Letters Patent on any patent
application within the Patent Rights or disputes or directly or indirectly assists any third party to dispute the validity of any patent within the Patent Rights, or any of the claims thereof, Wake
forest will be entitled thereafter to terminate immediately all or any portion of the License granted hereunder by notice thereof to KCI. 

        11.12 If
KCI elects not to pay the floor royalty of $[***] semi-annually as provided in Section 4.3 and Wake Forest exercises its
option to terminate, or upon termination of the License under this Agreement for any reason other than the expiration of the last expiring patent within the Patent Rights, KCI will give Wake Forest
KCI's studies, assessments, marketing information, manufacturing drawings, and molds (unless such molds will be retooled for other products) relating to the Licensed Products and/or the Licensed
Processes and Wake Forest can make whatever use of such materials and information that Wake Forest deems appropriate, including providing such materials and information to a third party for commercial
purposes. 

	12.
	Infringement

        12.1 Each
party will promptly inform the other in writing of any alleged infringement of the Patent Rights by a third party, or the assertion of a declaratory judgment
action alleging invalidity or noninfringement, and provide such other party with any available information about the infringement or declaratory action, as the case might be. Following such notice,
KCI may place [***] first accruing to Wake Forest following the expiration of a thirty day period after such notice into an escrow account as escrowed litigation royalties. KCI
will not settle or compromise any claim or action in a manner that imposes any restrictions or obligations on Wake Forest without Wake Forest's written consent, which consent will not be unreasonably
withheld. 

        12.2.1 During
the term of this Agreement, KCI will prosecute [***] any infringements of the Patent Rights, and, in furtherance of such right, KCM may
join Wake Forest as a party in any such suit, [***] to Wake Forest. As between wake Forest and KCI, KCI will be liable for [***] in such action and KCI
will be responsible, except as provided in Section 12.2.3, for the [***] in such an action. 

10

 

        12.2.2 As
a first option for KCI, [***]. Upon settlement or final termination of such action, KCI will immediately pay all escrowed litigation
royalties to Wake Forest. 

        12.2.3 As
an alternative option, [***]. All remaining escrowed litigation royalties will be immediately returned to Wake Forest. Wake Forest will
not, under any circumstances, be liable for any amounts in excess of the escrowed litigation royalties. 

        12.2.4 If,
within 6 months after having been notified of any alleged infringement of the Patent Rights, KCI will have been unsuccessful in persuading the alleged
infringer to desist and will not have brought and will not be diligently prosecuting an infringement action, or if KCI notifies Wake Forest at any time prior thereto of its intention not to bring suit
against any such alleged infringer, then (a) [***] and, (b) [***]. No settlement, consent judgment, or other voluntary fiscal disposition
of the suit may be entered into without the consent of KCI, which consent will not unreasonably be withheld. 

        12.3.1 In
the event that a Declaratory Judgment Action alleging invalidity or non-infringement of any of the Patent Rights will be brought against KCI or Wake
Forest, [***]. 

        12.3.2 As
a first option for KCI, [***]. Upon settlement or final termination of such action, provided such action does not result in a final
non-appealable or non-appealed decision that the subject patent(s) are invalid or unenforceable, [***]. If the subject patents are found to be invalid
or unenforceable in a final non-appealable or non-appealed decision, [***] if valid patents covering such products or processes still remain within the
Patent Rights. 

        12.3.3 As
an alternative option, [***]. All remaining escrowed litigation royalties will be immediately returned to Wake Forest. Wake Forest will
not, under any circumstances, be liable for any amounts in excess of the escrowed litigation royalties. 

        12.3.5 If
KCI is not diligently prosecuting or defending any Declaratory Judgment Action, then (a) [***] and
(b) [***]. No settlement, consent judgment or other voluntary fiscal disposition of the suit may be entered into without the consent of KCI, which consent will not
unreasonably be withheld. 

        12.4.1 KCI
will have a duty to defend any suit or counterclaim brought against Wake Forest or KCI for alleged infringement of any patent of any third party, to the extent
such suit is based upon a claim that the infringement arises from the manufacture, use or sale by KCI of products and/or processes within the Patent Rights pursuant to this Agreement. As between Wake
Forest and KCI, [***]. 

        12.4.2 Each
party will promptly inform the other in writing of the commencement of any such infringement action by a third party. Following such notice, KCI may place up to
a maximum of [***] into an escrow account as escrowed litigation royalties. KCI will not settle or compromise any such action in a manner that imposes any restrictions or
obligations on Wake Forest without Wake Forest's written consent, which consent will not be unreasonably withheld. 

        12.4.3 [***]
any such infringement action by any third party [***]. All remaining escrowed litigation royalties will be
promptly returned to Wake Forest. [***]. 

        12.4.4 Any
recovery of damages by KCI in any such infringement action by any third party in which escrowed litigation royalties of Wake Forest were used by KCI
[***]. 

        12.4.5 If
the exercise of the rights granted KCI herein infringe the rights of a third party, Wake Forest may elect to pursue a license from such third party that would
permit KCI to exercise the rights granted herein without limitation or interruption and without payments by KCI, or Wake Forest may authorize KCI to pursue such a license. In the event Wake Forest
authorizes KCI to secure such a license, and the terms of such a license provide for royalties or other payments by KCI to such third party, then the parties will negotiate in good faith, a royalty
reduction in the earned royalty rate set forth in Section 4.2 and the minimum royalty, but not the floor royalty, set forth in Section 4.3 such that the total royalties payable are
commercially reasonable. 

11

 

        12.4.6 If
the exercise of the rights granted KCI herein are found to infringe the rights of a third party in a decision that is final and non-appealable or
non-appealed, and neither Wake Forest nor KCI are able to secure a license from such third party, all remaining escrowed litigation royalties will be given to KCI, provided that KCI
provides written notice to Wake Forest of KCI's election to terminate the License under this Agreement. 

	13.
	Product
Liability 

        13.1 Except
as specifically provided otherwise under Section 12 of this Agreement, KCI and its sublicensees will, at all times during the term of this Agreement and
thereafter, indemnify, hold harmless and defend Wake Forest, its trustees, officers, employees and affiliates against all claims and expenses, including legal expenses and reasonable attorneys' fees,
arising out of any loss, claim, damage, or liability of whatsoever kind or nature which may arise at any time out of or in connection with any activity of KCI involving the Licensed Products or
Licensed Processes or Preissuance Products or Processes or the Patent Rights, including without limitation the use, sale, or distribution of any product derived from or using the Licensed Products or
Licensed Processes or Preissuance Products or Processes or the Patent Rights. 

        13.2 KCI
and its sublicensees will carry liability insurance at its expense, adequate to assure its obligations to Wake Forest under this section. KCI will include
satisfactory evidence of adequate insurance coverage with each semi-annual report required by Section 9. 

	14.
	Assignment 

        KCI
may assign or otherwise transfer this Agreement and the License granted hereby and the rights acquired by it hereunder so long as such assignment or transfer will be accompanied by a
sale or other transfer of KCI's entire business or of that part of KCI's business to which the License granted hereby relates. KCI will give Wake Forest 30 days prior notice of such assignment
and transfer and if Wake Forest raises no reasonable objection to such assignment or transfer in writing within 30 days after the giving of such notice and stating the reasons for such
objection, then Wake Forest will be deemed to have approved such assignment or transfer; provided, however, Wake Forest will not be deemed to have approved such assignment and transfer unless such
assignee or transferee will have agreed in writing to be bound by the terms and conditions of this Agreement. Upon such assignment or transfer and agreement by such assignee or transferee, the term
KCI as used herein will include such assignee or transferee. If KCI sells or otherwise transfers its entire business or that part of its business to which the License granted hereby relates and the
transferee will not have agreed in writing to be bound by the terms and conditions of this Agreement, or new terms and conditions will not have been agreed upon within 60 days of such sale or
transfer, Wake Forest will have the right to terminate the License under this Agreement. 

	15.
	Non-Use
of Names 

        KCI
will not use the names of Wake Forest or of The Inventors, nor any adaptation thereof in any advertising, promotional or sales literature without prior written consent obtained from
Wake Forest in each case, except that KCI may state that it is licensed by Wake Forest under one or more of the patents and/or applications comprising the Patent Rights. 

	16.
	Export
Controls 

        It
is understood that Wake Forest is subject to United States laws and regulations controlling the export of technical data, computer software, laboratory prototypes and other
commodities and that the activities of KCI may require a license from the relevant agency of the United States Government and/or written assurances by KCI that KCI will not export data or commodities
to certain foreign countries without prior approval of such agency. Wake Forest neither represents that a license will not be required nor that, if required, it will be issued. 

12

 

	17.
	Payments,
Notices and Other Communications 

        Any
payment, notice, or other communication pursuant to this Agreement will be sufficiently made or given an the date of mailing if sent to such party by certified first class mail,
postage prepaid, addressed to it at its address below or as it will designate by written notice given to the other party: 

	Wake Forest:	Julie M. Watson

Technology Transfer Service

Wake Forest University

The Bowman Gray School of Medicine

Medical Center Boulevard

Winston-Salem, North Carolina 27157
	

KCI:	

Peter A. Leininger, M.D.

Director and Senior Vice President

Kinetic Concepts, Inc.

8023 Vantage Drive

San Antonio, Texas 78216

	18.
	Miscellaneous
Provisions 

        18.1 This
Agreement will be construed, governed, interpreted, and applied in accordance with the laws of the State of North Carolina, U.S.A., except that questions affecting
the construction and effect of any patent will be determined by the law of the country in which the patent was granted. 

        18.2 The
parties hereto acknowledge that this Agreement sets forth the entire agreement and understanding of the parties hereto as to the subject matter hereof, and will not
be subject to any change or modification except by the execution of a written instrument subscribed to by the parties hereto. 

        18.3 The
provisions of this Agreement are severable, and in the event that any provision of this Agreement will be determined to be invalid or unenforceable under any
controlling body of law such invalidity or unenforceability will not in any way affect the validity or enforceability of the remaining provisions hereof. 

        18.4 KCI
agrees to mark the Licensed Products sold in the United States with all applicable United States patent numbers. All Licensed Products shipped to or sold in other
countries will be marked in such a manner as to conform with the patent laws and practice of the country of manufacture or sale. 

        18.5 The
failure of either party to assert a right hereunder or to insist upon compliance with any term or condition of this Agreement will not constitute a waiver of that
right or excuse a similar subsequent failure to perform any such term or condition by the other party. 

        18.6 In
any litigation arising under or relating to this Agreement between the parties hereto, the prevailing party or parties will be entitled to recover its reasonable
attorneys fees and litigation costs. 

        18.7 Except
as otherwise specifically provided in Section 14 of this Agreement, neither this Agreement nor any of the licenses or rights herein granted will be
assignable or otherwise transferable by KCI without the prior written permission of Wake Forest. 

        18.8 This
Agreement will be binding and inure to the benefit of the parties hereto and their respective Affiliates, and permitted successors and assigns. 

        18.9 The
representations, warranties, covenants, and undertakings contained in this Agreement are for the sole benefit of the parties hereto and their permitted successors
and assigns and such 

13

 

representations,
warranties, covenants, and undertakings will not be construed as conferring any rights on any other party. 

        18.10 Nothing
contained in this Agreement will be deemed to place the parties hereto in a partnership, joint venture or agency relationship and neither party will have the
right or authority to obligate or bind the other party in any manner. 

        18.11 This
Agreement may be executed in two or more counterparts, each of which will be deemed an original, but all of which taken together will constitute one and the same
instrument. 

        18.12 A
party to this Agreement will be excused from any performance required hereunder if such performance is rendered impossible or commercially impracticable due to a
catastrophe or other event, including without limitation, war, riot and insurrection, laws, proclamations, edicts, ordinances or regulations, including a health emergency; strikes, lockouts or other
serious labor disputes; and floods, fires, explosions or other natural disasters. 

IN
WITNESS WHEREOF, the parties hereto have hereunto set their hands and seals and duly executed this License Agreement the day and year first set forth below. 

	WAKE FOREST UNIVERSITY	 	KINETIC CONCEPTS, INC.
	

By:	

/s/  J. KIFFIN PENRY      	
 	

By:	

/s/  JAMES R. LEININGER, M.D.      
	 	
	 	 	

	Name:	J. Kiffin Penry, M.D.	 	Name:	James R. Leininger, M.D.
	Title:	Senior Associate Dean	 	Title:	CEO and President
	

Date:	

10/5/93	
 	

Date:	

10/6/93
	 	
	 	 	

14

 
 
 

APPENDIX A

    
    

System and Method for Achieving Rapid Wound Healing

Louis C. Argenta and Michael J. Morykwas

	Serial No:

Filed:	 	07/792,001

November 14, 1991
	

Serial No:

Filed:	
 	

PCT/US92/09649

November 12, 1992
	

Serial No:

Filed:	
 	

08/028,677 (CIP of 07/792,001)

March 9, 1993

15

 
 
 

APPENDIX B    
    

Wound Dressing and Treatment Method

David S. Zamierowski

Patent No: 4,969,880

Issued: November 13, 1990 

Fluidic Connection System and Method

David S. Zamierowski

Patent No: 5,100,396 (CIP of 4,969,880)

Issued: March 31, 1992 

Fastening System and Method

David S. Zamierowski

Serial No: 07/699,936

Filed: May 14, 1991 

Fastening System and Method

David S. Zamierowski

Serial No: PCT/US92/04019

Filed: May 14, 1992 

16

 
 
 

APPENDIX C    
    

YEAR
ONE RESEARCH

TOTAL [***] 

	1.
	Determination
of optimal vacuum levels (inches Hg) to maximize superficial and deep tissue perfusion levels as determined by laser doppler needle probes and superficial tissue
O2 and CO2 levels with transcutaneous probes. Studies are needed to determine the maximum and minimum boundaries of applied vacuum and also the optimal vacuum level to maximize
perfusion in sensate and cord injured patients. (The lack of vascular tone in cord injured patients may result in different responses to applied vacuum than sensate patients.)
$[***]

	2.
	Effects
of intermittent vacuum timing on superficial and deep tissue perfusion as determined by laser doppler needle probes. Studies are needed to determine the optimal cycle
conditions; whether symmetrical or asymmetrical. If asymmetrical, then duration of on and off periods needs to be determined for both sensate and cord injured patients. $[***] 

Major
Equipment 

MBF3D—Dual
Channel Microvascular Laser Doppler Blood Flow

                Monitor with 4 needle probes

                Moor Instruments Ltd. Devon England

                Can be used for both human (1&2) studies $[***] 

17

        22 December, 2000 

        Confidential

Kinetic
Concepts, Inc. ("KCI"),

a Texas corporation

8023 Vantage Drive

San Antonio, Texas 78230-4726 

Wake
Forest University ("Wake Forest"),

a North Carolina educational institution

through its Wake Forest University School of Medicine

Medical Center Boulevard

Winston-Salem, North Carolina 27157

Attention: Office of Technology Asset Management 

	Re:
	 Amendment to License Agreement dated October 6, 1993 (the "Agreement")  

Gentlemen: 

        We
have been discussing amendments to our License Agreement dated October 6, 1993 (herein, the "Agreement"). This letter (hereinafter, this "Amendment") documents such amendments,
which are made principally for relieving KCI of certain near term obligations in hopes of enabling longer term market penetration, for our mutual benefit. 

Adjusted Royalty Calculations  

        Section 4.4.2 of the Agreement is hereby amended by adding the following sentence at the end thereof: The royalty reduction to the amount of earned royalty
to be paid by KCI to Wake Forest as a result of royalty payments to be made by KCI to Zamierowski as provided under Section 4.4.2 shall not be affected by any temporary relief of the actual
payment by KCI of any royalty obligations due to Dr. Zamierowski for the period ("Time Period of Relief") beginning on July 1, 2000 and ending on December 31, 2002. As such, for
the Time Period of Relief, the term "royalty payments actually paid to Zamierowski" as used in the first sentence of 4.4.2 of the Agreement shall be deemed to include both royalty payments actually
made by KCI to Zamierowski as well as any royalty payments that would have accrued to Zamierowski but not actually paid by KCI due to temporary relief during the Time Period of Relief. 

        In
addition, Article 4, "Compensation," of the Agreement is hereby amended by adding the following additional paragraphs: 

        4.9.1 For
purposes of this Agreement, "Domestic Royalties" means that portion of the earned royalty due for Net Sales of Licensed Products or Licensed Processes in the
United States. "International Royalties" means that portion of the earned royalty due for Net Sales of Licensed Products or Licensed Processes outside of the United States. 

        4.9.2 For
the six-month period ending the last day of December, 2000 and for such period only, after all other calculations of earned royalty under this
Agreement, the amount of Domestic Royalties due for that period shall be reduced by [***] dollars $[***]. Any minimum royalty obligations far such
six-month period ending on December 31, 2000 shall not apply. 

        4.9.3 As partial consideration for the royalty reduction provided in Section 4.9.2, and beginning with the semi-annual royalty report and corresponding
payment (the "Report") due to be submitted the last day of February, 2001, and ending with the Report due to be submitted the last day of August, 2002, KCI shall advance payment for Domestic Royalties
prospectively ("Prospective Payments") for the then-current semi-annual periods ("Halves" or "Half Years"). Payments for International Royalties are not affected by this
Amendment and are due and payable as provided for in the Agreement. Prospective Payments shall be based on the following

 

projections
for the corresponding Halves of calendar years 2001 and 2002, unless otherwise mutually agreed to in writing: 

	YEAR
 
	 	Projected Domestic

Net Sales For

First Half
	 	Projected Domestic

Net Sales for

Second Half

	2001	 	$	[***]	 	$	[***]
	2002	 	$	[***]	 	$	[***]

        For
any Half Year in which Prospective Royalties have been paid, any difference between the Prospective Payments actually made by KCI to Wake Forest for such Half Year and the amount of
Domestic Royalties actually earned for such Half Year ("Corrections") will be accounted for in the next succeeding Report following such Half Year. Notwithstanding the foregoing, the Report due to be
submitted the last day of February 2001, shall also include accounting for Domestic Royalties earned for the second Half Year of 2000; whereas the Domestic Royalties of all other Reports due to Wake
Forest in years 2001 and 2002 shall be limited to the Prospective Payments, the Added Domestic Royalty as described in Paragraph 4.9.4 of this Agreement (to the extent applicable), and any
Corrections. After the August 2002 Report for the prospective period ending on December 31, 2002, the Prospective Payment provisions of this Paragraph 4.9.3 shall no longer apply and
royalties shall again be paid retrospectively, as set forth elsewhere in this Agreement, provided, however, that KCI shall make any applicable Correction in the Report of February 2003 for the Half
Year ending on December 31, 2002.

 

        4.9.4 As
partial consideration for the royalty reduction provided in Section 4.9.2 and in addition to the other payment obligations set forth in this Agreement,
beginning January 1, 2000, KCI shall owe an Added Domestic Royalty (defined below) to Wake Forest until the date on which the cumulative total of such Added Domestic Royalty actually paid to
Wake Forest equals [***] ($[***]). The "Added Domestic
Royalty" shall be calculated retrospectively as [***]% of Net Sales of Licensed Products or Licensed Processes in the United States during each Half Year commencing with the
Half Year of January 1, 2001 through June 30, 2001. The Added Domestic Royalty shall be paid by KCI to Wake Forest with the Report for each Half Year. The first payment for the Added
Domestic Royalty is not due until the Report of [***] for the Half Year ending on June 30, 2001. 

        4.9.5 In
partial consideration for the royalty reduction provided in Section 4.9.2, KCI will also pay to Wake Forest a minimum U.S. royalty of
[***] ($[***]) (the "Transition Minimum"), in addition to any International Royalties due and payable, with the Report due on the last day of
[***] (the "Transition Report"). Any Domestic Royalties (including Added Domestic Royalties) paid with the Transition Report will be credited against said Transition Minimum,
and the amount of the Transition Minimum which exceeds such Domestic Royalties shall be credited to KCI as a royalty credit ("Royalty Credit"). KCI shall have the right to apply its unused Royalty
Credit with subsequent Reports in amounts not to exceed [***] ($[***]) per Report. 

        4.9.6 If
KCI terminates this Agreement prior to January 1, 2004 for any reason other than material breach by Wake Forest resulting in damages awarded to KCI of at
least $[***] or if Wake Forest terminates this Agreement prior to January 1, 2004 due to an uncured material breach by KCI, then KCI will pay a termination fee of
[***] ($[***]) to Wake Forest within thirty (30) days following such termination. 

Escrow Provisions  

        Section 12.1 of the Agreement is hereby amended by deleting the second sentence of Section 12.1 in its entirety and replacing the deleted sentence
with the following sentence: "Thirty (30) days following such notice, KCI may escrow a portion of the royalties payable to Wake Forest in any one 

2

 

payment
period, the aggregate of said-escrowed royalties not to exceed [***] KCI's direct, out-of-pocket expenses paid by KCI during that
same and prior periods in direct relation to (i) prosecuting a defense against a declaratory judgment action by a bona fide third party alleging invalidity or non-infringement of
the Patent Rights, or (ii) filing and prosecuting an infringement action against a bona fide third party for infringement of the Patent Rights; provided that said escrowed royalties are no
greater than [***]% the total royalties payable to Wake Forest in that same payment period." 

Controlling Terms  

        The terms of this Amendment shall control over the terms of the original Agreement which are inconsistent with this Amendment. Any and all other terms of the
Agreement remain in full force and effect. 

        Now
therefore, in consideration of the foregoing mutual covenants and for other good and valuable consideration, the sufficiency of which is hereby acknowledged and agreed, the Parties
hereby agree that the terms of this Amendment amend the Agreement. In witness whereof, each Party has caused this Amendment to be executed by its duly authorized representative, to be effective as of
July 1, 2000. 

ACKNOWLEDGED AND AGREED:  

	Kinetic Concepts, Inc.	 	Wake Forest University

through its Wake Forest University of

School of Medicine
	

By:	

/s/  FRANK DILAZZARO      	
 	

By:	

/s/  RICHARD H. DEAN      
	 	
	 	 	

	 	Frank DiLazzaro

Senior Vice President	 	 	Richard H. Dean, M.D.

Senior Vice President for Health Affairs
	

Date:	

12-22-2000	
 	

Date:	

12-22-2000
	 	
	 	 	

3

QuickLinks

Exhibit 10.29

WAKE FOREST UNIVERSITY LICENSE AGREEMENT

APPENDIX A

APPENDIX B

APPENDIX CQuickLinks
 -- Click here to rapidly navigate through this document

Exhbit 10.30  

 
 

WH HOLDINGS (CAYMAN ISLANDS) LTD.
  STOCK INCENTIVE PLAN
  (as restated on November 5, 2003)    
    

        1.     Purpose of Plan.

        The
WH Holdings (Cayman Islands) Ltd. Stock Incentive Plan (the "Plan") is designed: 

        (a)   to
promote the long term financial interests and growth of WH Holdings (Cayman Islands) Ltd. (the "Company") and its affiliates by attracting and retaining
employees with the training, experience and ability to enable them to make a substantial contribution to the success of the business of the Company and its affiliates; 

        (b)   to
motivate employees by means of growth-related incentives to achieve long range goals; 

        (c)   to
further the alignment of interests of participants with those of the equityholders of the Company through opportunities for increased ownership in the Company; and 

        (d)   to
be a written compensatory benefit plan within the meaning of Rule 701 promulgated under the Securities Act. 

        2.     Definitions.

        As
used in the Plan, the following words will have the following meanings: 

        (a)   "Affiliate" means, with respect to the Company, any corporation directly or indirectly controlling, controlled by, or
under common control with, the Company or any other entity designated by the Committee in which the Company or an Affiliate has an interest. 

        (b)   "Board" means the Board of Directors of the Company. 

        (c)   "Change of Control" means an Organic Transaction as defined in the Amended and Restated Memorandum and Articles of
Association of the Company. 

        (d)   "Code" means the Internal Revenue Code of 1986, as amended. 

        (e)   "Committee" means one or more committees each comprised of not less than three members of the Board appointed by the
Board to administer the Plan or a specified portion thereof; provided, however, that if, at any time, there will be only one director serving on the
Board, the Committee may be composed of the sole director. Unless otherwise determined by the Board, if the Common Shares become registered under Section 12 of the Exchange Act and if the
Committee is authorized to grant Options subject to Section 16 of the Exchange Act, each member of the Committee will be a "non-employee director" within the meaning of applicable
Rule 16b-3 under the Exchange Act. 

        (f)    "Common Shares" means the common shares, par value $0.001 per share, of the Company. 

        (g)   "Employee" means a person, including an officer, in the employment of the Company or one of its Affiliates who, in the
opinion of the Committee, is, or is expected to be, primarily responsible for the management, growth or protection of some part or all of the business of the Company. 

        (h)   "Exchange Act" means the Securities Exchange Act of 1934, as amended. 

        (i)    "Exercise Price" means the price at which a Participant may purchase a Common Share, as provided in the Option Agreement. 

        (j)    "Fair Market Value" means the fair market value of a Share as of a particular date. If at any such time such Shares are
not listed or admitted for trading on any national securities 

exchange
or quoted on Nasdaq or a similar service, the Fair Market Value for such Shares means the fair market value of such Shares at such time as determined in good faith by the Committee. However,
subsequent to an Initial Public Offering, the Fair Market Value of a Common Share will be the average of high bid and low asked prices of Common Shares as reported on the exchange on which it is
listed as of such date, or if no such quotation is made on such date, the immediately preceding day on which there were quotations as reported in The Wall Street
Journal. 

        (k)   "Grant" means an award made to a Participant pursuant to the Plan and described in Paragraph 5. 

        (l)    "Incentive Stock Option" means an Option which satisfies all of the applicable requirements of Code Section 422. 

        (m)  "Initial Public Offering" means the underwritten public offering by the Company of its Common Shares pursuant to a
registration statement (other than a registration statement relating solely to an employee benefit plan or transaction covered by Rule 145 of the Securities Act) that has been filed under the
Securities Act and declared effective by the Securities and Exchange Commission, or any other Federal agency at the time administering the Securities Act. 

        (n)   "Non-Statutory Stock Option" means an Option which does not satisfy all of the applicable requirements of
Code Section 422 or which by its terms is not intended to be treated as an Incentive Stock Option. 

        (o)   "Option" means an option to purchase Common Shares. 

        (p)   "Option Agreement" means an agreement between the Company and a Participant that sets forth the terms, conditions and
limitations applicable to an Option Grant. 

        (q)   "Optionee" means an individual who holds an Option. 

        (r)   "Participant" means an Employee or Consultant of the Company or one of its Affiliates, to whom one or more Grants have
been made and such Grants have not all been forfeited or terminated under the Plan. 

        (s)   "Preferred Shares" means Preferred Shares as defined in the Amended and Restated Memorandum and Articles of Association
of WH Holdings (Cayman Islands) Ltd. and known as the "12% Series A Cumulative Convertible Preferred Shares". 

        (t)    "SAR" means a stock appreciation right granted under the Plan. 

        (u)   "SAR Agreement" means an agreement between the Company and a Participant that sets forth the terms, conditions and
limitations applicable to a SAR Grant. 

        (v)   "Securities Act" means the Securities Act of 1933, as amended. 

        (w)  "Share" means a share of Common Shares. 

        (x)   "Shareholders' Agreement" means the shareholders' agreement, dated as of July 31, 2002, by and among WH Holdings
(Cayman Islands) Ltd., Whitney V, L.P., Whitney Strategic Partners V, L.P., and WH Investments Ltd., and CCG Investments (BVI), L.P., CCG Associates-QP, LLC, CCG
Associates-AI, LLC, CCG GP Fund LLC, CCG Investment Fund-AI, LP, CCG AV, LLC-Series C, CCG AV, LLC-Series E and CCG CI, LLC, and certain
other persons who may, from time to time, become party to the agreement. 

        (y)   "Subsidiary" means any entity in an unbroken chain of entities beginning with the Company if each of the entities, or
group of commonly controlled entities, other than the last entity in the unbroken chain then owns 50% or more of the total combined voting power of the other entities in such chain. 

        (z)   "Total Exercise Cost" means an amount equal to the Exercise Price multiplied by the number of Shares being purchased
pursuant to the Option. 

        3.     Administration of Plan.

        (a)   The
Plan will be administered by the Committee. The Committee may adopt its own rules of procedure. Action of a majority of the members of the Committee taken at a
meeting, or action taken without a meeting by unanimous written consent, will constitute action by the Committee. The Committee will have the power and authority, in its discretion: 

	(i)
	to
select the Participants to whom Grants may be made hereunder;

	(ii)
	to
determine the number of Shares to be covered by each Grant made hereunder;

	(iii)
	to
approve forms of Option and SAR Agreements for use under the Plan;

	(iv)
	to
determine the terms and conditions, not inconsistent with the terms of the Plan, or any Grant made hereunder;

	(v)
	to
construe and interpret the terms of the Plan and Grants made under the Plan;

	(vi)
	to
adopt rules and procedures relating to the operation and the administration of the Plan to accommodate the specific requirements of local laws and procedures. Without limiting the
generality of the foregoing, the Committee is specifically authorized (A) to adopt the rules and procedures regarding the conversion of local currency, withholding procedures and handling of
stock certificates which vary with local requirements, and (B) the adopt sub-plans and Plan addenda, as the Committee deems desirable, to accommodate foreign tax laws, regulations
and practice;

	(vii)
	to
prescribe, amend and rescind rules and regulations relating to the Plan, including rules and regulations relating to sub-plans and Plan addenda;

	(viii)
	to
authorize any person to execute on behalf of the Company any instrument required to effect a Grant previously made by the Committee; and

	(ix)
	to
make all other determinations deemed necessary or advisable for administering the Plan and any Grants made hereunder. 

        (b)   The
Committee may employ attorneys, consultants, accountants, appraisers, brokers or other persons. The Committee, the Company, and the officers of the Company will be
entitled to rely upon the advice, opinions or valuations of any such persons. All actions taken and all interpretations and determinations made by the Committee in good faith will be final and binding
upon all Participants, the Company and all other interested persons. No member of the Committee will be personally liable for any action, determination or interpretation made in good faith with
respect to the Plan or the Grants, and all members of the Committee will be fully protected by the Company with respect to any such action, determination or interpretation. 

        4.     Eligibility.

        Subject
to Paragraph 5(a), the Committee may from time to time make Grants under the Plan to such Employees of the Company or any of its Affiliates, and in such form and having
such terms, conditions and limitations as the Committee may determine. Prior to participation in the Plan, the Committee may require any Participant to execute a Release and Waiver to Rights to
payments and benefits under certain plans of Herbalife International, Inc. Grants may be made singly, in combination or in tandem. The terms, conditions and limitations of each Grant under the
Plan will be set forth in an Option Agreement or SAR Agreement (as the case may be), in a form or forms approved by the Committee; provided, however,  that such Option Agreement or SAR Agreement will
contain provisions dealing with the treatment of Grants in the event of the termination, death or disability of a Participant,
and may also include provisions concerning the treatment of Grants in the event of a Change of Control of the Company. Notwithstanding the foregoing, Incentive Stock Options may only be granted to
Employees. 

        5.     Grants.

        (a)   The
Committee may grant Incentive Stock Options only to Employees of the Company or any "subsidiary corporation" within the meaning of Code Section 424(f). The
Plan provides for grants only
to Employees for Incentive Stock Options and for grants to Employees and consultants for Non-Statutory Stock Options. 

        (b)   At
the time of the Grant, the Committee will determine, and will include in the Option Agreement, SAR Agreement or other Plan rules, the exercise price and such other
conditions and restrictions on the grant or exercise of the Option or SAR as the Committee deems appropriate. 

        (c)   In
addition to any other restrictions contained in the Plan, an Option or SAR granted under the Plan may not be exercised more than 10 years after the date it is
granted. An Incentive Stock Option may not have an exercise price of less than 100% of the Fair Market Value of a Share on the date the Option is granted. 

        (d)   If
the aggregate Fair Market Value (determined on the date the Option is granted) of a Share subject to an Incentive Stock Option which is exercisable for the first time
during any calendar year exceeds $100,000, then the portion of the Incentive Stock Option in excess of the $100,000 limitation will be treated as a Non-Statutory Stock Option. If an
Incentive Stock Option is granted to a Participant who, at the time the Option is granted, is deemed to own more than 10% of the total combined voting power of all classes of shares of the Company or
any "subsidiary corporation" of the Company (as more fully described in Code Section 422(b)(6)), then (i) the exercise price of the Option may not be less than 110% of the Fair Market
Value of the Common Shares on the date the Option is granted, and (ii) such Option may not be exercisable after the expiration of five years from the date the Option is granted. 

        (e)   Payment
of the Option exercise price will be made in cash or, if subsequent to an Initial Public Offering, through the delivery of irrevocable instructions to a broker
to deliver promptly to the Company an amount equal to the Option exercise price, in accordance with the terms of the Plan, the Option Agreement and of any applicable guidelines of the Committee in
effect at the time, and subject to increase for any applicable withholding requirements. 

        (f)    Prior
to or upon exercise of an Option, the Committee may determine, at its discretion, to pay to the Participant an amount of cash equal to the amount by which the Fair
Market Value (on the date of exercise) of the Shares subject to the Option exceeds the Option exercise price. In this case, the Participant will not receive any Shares and will not have to pay the
Option exercise price. 

        (g)   Upon
exercise of a SAR, the Participant shall receive from the Company (a) Shares, (b) cash, or (c) a combination of Shares and cash, as the
Committee shall determine, at its discretion, unless the method of payment has been prescribed in the SAR Agreement. The amount of cash and/or the Fair Market Value of the Shares received upon
exercise of the SAR shall, in the aggregate, be equal to the amount by which the Fair Market Value (on the date of exercise) of the Shares subject to the SAR exceeds the exercise price. 

        6.     Limitations and Conditions.

        (a)   The
total number of Shares available for Grants under the Plan will be 18,717,546, reduced by any Shares granted under the WH Holdings (Cayman Islands) Ltd.
Executive Officer Stock Option Plan and the WH Holdings (Cayman Islands) Ltd. Independent Directors Stock Option Plan, subject to adjustment in accordance with Paragraph 7 or 8 hereof.
If an Option or SAR expires, is canceled, forfeited or otherwise terminated without being exercised or settled, the Shares allocable to the unexercised portion of such Option or SAR shall remain
available for grant under the Plan. Notwithstanding the foregoing, in no event shall the aggregate number of Shares to be issued hereunder in any rolling twelve-month period exceed the number of
Shares that the Company is permitted to issue pursuant to the exemption from registration provided by Rule 701 of the Securities Act. 

        (b)   No
Grants will be made under the Plan more than 10 years after the date the Plan is adopted by the Board or is approved by the shareholders of the Company,
whichever is earlier, but the terms of Grants made on or before the expiration of the Plan may extend beyond such expiration. At the time a Grant is made or amended or the terms or conditions of a
Grant are changed, the Committee may provide for limitations or conditions on such Grant. 

        (c)   Nothing
contained herein will affect the right of the Company, an Affiliate or a Subsidiary to terminate any Participant's employment or services at any time or for any
reason. 

        (d)   Other
than as specifically provided with regard to the death of a Participant or as hereinafter provided, no benefit under the Plan will be subject in any manner to
anticipation, alienation, sale, transfer, assignment, pledge, encumbrance, or charge, and any attempt to do so will be void. No such benefit will, prior to receipt thereof by the Participant, be in
any manner liable for or subject to the debts, contracts, liabilities, engagements, or torts of the Participant. 

        (e)   Participants
will not be, and will not have any of the rights or privileges of, equityholders of the Company in respect of any Shares purchasable in connection with any
Grant unless and until certificates representing any such Shares have been issued by the Company to such Participants. Prior to an Initial Public Offering, each Participant will be required to enter
into the Shareholders' Agreement with the Company, or execute a joinder to the Shareholders' Agreement in a form provided by the Company, upon the exercise of any Option or SAR and the issuance of
Shares under the Plan. 

        (f)    No
election as to benefits or exercise of Options or SARs, or other rights may be made during a Participant's lifetime by anyone other than the Participant except by a
legal representative appointed for or by the Participant. 

        (g)   Absent
express provisions to the contrary, any Grant under the Plan will not be deemed compensation for purposes of computing benefits or contributions under any
retirement plan of the Company, its Affiliates or its Subsidiaries and will not affect any benefits under any other benefit plan of any kind now or subsequently in effect under which the availability
or amount of benefits is related to level of compensation. The Plan is not an "employee benefit plan" under Section 3(3) of the Employee Retirement Income Security Act of 1974, as amended. 

        (h)   Unless
the Committee determines otherwise, no benefit or promise under the Plan will be secured by any specific assets of the Company, its Affiliates or any of its
Subsidiaries, nor will any assets of the Company, its Affiliates or any of its Subsidiaries be designated as attributable or allocated to the satisfaction of the Company's obligations under the Plan. 

        (i)    Any
right of the Company to repurchase Shares, as determined under an Option Agreement, shall terminate following an Initial Public Offering. 

        7.     Adjustments.

        In
the event of any change in the outstanding Shares by reason of an acquisition, spin-off or reclassification, recapitalization or merger, combination or exchange of Shares
or other corporate exchange, Change of Control or similar event, or as required under any Option Agreement or SAR Agreement, the Committee may adjust appropriately the number or kind of Shares or
securities subject to the Plan and available for or covered by Grants and exercise prices related to outstanding Grants and make such other revisions to outstanding Grants as it deems are equitably
required. Any such adjustments for Incentive Stock Options must meet the requirements of Code Section 424(a). 

        8.     Merger, Consolidation, Exchange, Acquisition, Liquidation or Dissolution.

        In
its absolute discretion, and on such terms and conditions as it deems appropriate, coincident with or after the grant of any Option or SAR, the Committee may provide, with respect to
the merger or consolidation of the Company into another corporation, the exchange of all or substantially all of the assets of the Company for the securities of another corporation, a Change of
Control or the recapitalization, reclassification, liquidation or dissolution of the Company, either (a) that such Option 

or
SAR cannot be exercised after such event, in which case the Committee may also provide (but will be under no obligation to provide), either by the terms of such Option or SAR or by a resolution
adopted prior to the occurrence of such event, that for some period of time prior to such event, such Option or SAR will be exercisable as to all Shares subject thereto which are exercisable, or, by
virtue of the event, become exercisable, notwithstanding anything to the contrary herein (but subject to the provisions of Paragraph 6(b)) or that the Option or SAR will be repurchased by the
Company at a specific price and that, upon the occurrence of such event, such Option or SAR will terminate and be of no further force or effect, or (b) that even if the Option or SAR will
remain exercisable after such event, from and after such event, any such Option or SAR will be exercisable only for the kind and amount of securities and/or other property, or the cash equivalent
thereof, receivable as a result of such event by the holder of a number of Shares for which such Option or SAR could have been exercised immediately prior to such event, or that the Option or SAR will
be repurchased by the Company at a specific price. 

        In
addition, in the event of a Change of Control, the Committee may, in its absolute discretion and on such terms and conditions as it deems appropriate, provide, either by the terms of
such Option or SAR or by a resolution adopted prior to the occurrence of the Change of Control, that such Option or SAR will be exercisable as to all or any portion of the Shares subject thereto,
notwithstanding anything to the contrary herein (but subject to the provisions of Paragraph 6(b)). 

        9.     Securities Law Requirements.

        (a)   Shares
shall not be issued under the Plan unless the issuance and delivery of the Shares comply with (or are exempt from) all applicable requirements of law, including
(without limitation) the Securities Act, the rules and regulations promulgated thereunder, state securities laws and regulations and the regulations of any stock exchange or other securities markets
on which the Company's securities may then be traded. 

        (b)   The
Company each year shall furnish to Optionees and shareholders who have received Shares under the Plan its balance sheet and income statement, if required to do so
pursuant to Rule 701 of the Securities Act unless such Optionees or shareholders are key Employees whose duties with the Company assure them access to equivalent information. Such balance sheet
and income statement need not be audited. 

        10.   Amendment and Termination.

        The
Board will have the authority to make such amendments to any terms and conditions applicable to outstanding Grants as are consistent with the Plan provided that, except for
adjustments under Paragraph 7 or 8, no such action will modify such Grant in a manner adverse to the Participant without the Participant's consent except as such modification is provided for or
contemplated in the terms of the Grant. 

        The
Board may amend, suspend or terminate the Plan except that no such action, other than an action under Paragraph 7 or 8, may be taken which would, without shareholder approval
(but only if such approval is necessary for exemption under Section 16(b) of the Exchange Act or to meet the applicable requirements of Code Section 422), increase the aggregate number
of Shares available for Grants under the Plan, change the eligible class of individuals, decrease the price of outstanding Options, change the requirements relating to the Committee or extend the term
of the Plan. 

        11.   Withholding Taxes.

        The
Company will have the right to deduct from any cash payment made under the Plan any federal, state or local income or other taxes required by law to be withheld with respect to such
payment. The Participant must pay to the Company such amount as may be requested by the Company for the purpose of satisfying any liability for such withholding taxes before the obligation of the
Company to deliver certificates for the Shares upon the exercise of an Option or SAR arises. Any Option Agreement or SAR Agreement may provide that the Participant may elect, in accordance with 

any
conditions set forth in such Option Agreement or SAR Agreement, to pay a portion or all of such withholding taxes in Shares. 

        12.   Governing Law.

        The
Plan will be governed by and construed and enforced in accordance with the laws of the State of New York, without regard to the conflicts of laws principles thereof. 

        13.   Non-U.S. Persons.

        Without
amending the Plan, the Committee may grant Options to eligible employees who are foreign nationals on such terms and conditions different from those specified in this Plan as may
in the judgment of the Committee be necessary or desirable to foster and promote achievement of the purposes of the Plan, and, in furtherance of such purposes, the Committee may make such
modifications, amendments, procedures, subplans and the like as may be necessary or advisable to comply with provisions of laws in other countries in which the Company or its Affiliates operates or
has employees. 

        14.   Effective Date and Termination Date.

        The
Plan will be effective on July 31, 2002 and will terminate on July 31, 2012, subject to earlier termination pursuant to Paragraph 10. 

APPENDIX A

PROVISIONS FOR CALIFORNIA RESIDENTS  

        The following sections shall supplement the sections set forth in the Plan, in the event of a conflict and shall supercede the applicable provision: 

        15.   Miscellaneous.

        (a)   Compliance
with Securities Laws; Listing and Registration. This Plan is intended to comply with Section 25102(o) of the California Corporations Code. Any
provision of this Plan which is inconsistent with Section 25102(o), including without limitation any provision of this Plan that is more restrictive than would be permitted by
Section 25102(o) as amended from time to time, shall, without further act or amendment by the Board or the Committee, be reformed to comply with the requirements of Section 25102(o). If
at any time the by the Board or the Committee determines that the delivery of Shares under the Plan is or may be unlawful under the laws of any applicable jurisdiction, or federal or state securities
laws, the right to exercise an Option or receive shares of Shares pursuant to an Option shall be suspended until the Board or the Committee determines that such delivery is lawful. The Company shall
have no obligation to effect any registration or qualification of the Shares under federal or state laws. 

        The
Company may require that an Optionee, as a condition to exercise of an Option, and as a condition to the delivery of any share certificate, make such written representations
(including representations to the effect that such person will not dispose of the Shares so acquired in violation of federal or state securities laws) and furnish such information as may, in the
opinion of counsel for the Company, be appropriate to permit the Company to issue the Shares in compliance with applicable federal and state securities laws. The certificates for any Shares issued
pursuant to this Plan may bear a legend restricting transferability of the Shares unless such Shares are registered or an exemption from registration is available under the Securities Act of 1933 and
applicable state securities laws. 

        (b)   Financial
Statements. The Company will provide financial statements to each Option recipient annually during the period such individual has Options outstanding, or as
otherwise required under Section 260.140.46 of Title10 of the California Code of Regulations. Notwithstanding the foregoing, the Company will not be required to provide such financial
statements to Option recipients when issuance is limited to key employees whose services in connection with the Company assure them access to equivalent information. 

        (c)   Voting
Rights. The Company will comply with Section 260.140.1 of Title 10 of the California Code of Regulations with respect to the voting rights of Stock. 

        (d)   Company's
Repurchase Option. At the discretion of the Board or the Committee, the Company may reserve to itself and/or its assignee(s) in the Option Agreement a right to
repurchase shares held by an Optionee for a period of ninety (90) days following the later of (i) 181 days after such Optionee exercises such Option or (ii) such Optionee's
termination from the Company for cash and/or cancellation of purchase money indebtedness, at: (A) with respect to vested shares, the Fair Market Value of such Shares on the Optionee's
termination date, provided, that such right to repurchase vested shares terminates following an Initial Public Offering; or (B) with respect to unvested shares, the Optionee's exercise price,
provided, that to the extent the Optionee is not an officer, director or consultant of the Company or of a Parent or Subsidiary to the Company, such right to repurchase unvested shares at the exercise
price lapses at the rate of at least twenty percent (20%) per year over five (5) years from the date of grant of the option. 

        (e)   Number
of Shares. At no time shall the total number of Shares issuable upon exercise of all outstanding options and the total number of Shares provided for under any
stock bonus or similar plan of the Company exceed the applicable percentage calculated in accordance with 260.140.45 of Title 10 of the California Code of Regulations. 

        (f)    Exercise
Price. The Exercise Price of a Non-Statutory Option shall not be less than 85% of the Fair Market Value of a Share on the date of grant. Subject to
the preceding sentence, the
Exercise Price under any Option shall be determined by the Committee in its sole discretion. If a Non-Statutory Stock Option is granted to a Participant who, at the time the Option is
granted, is deemed to own more than 10% of the total combined voting power of all classes of shares of the Company or any "subsidiary corporation" of the Company (as more fully described in Code
Section 422(b)(6)), then the Exercise Price of the Option may not be less than 110% of the Fair Market Value of the Shares on the date the Option is granted. 

QuickLinks

WH HOLDINGS (CAYMAN ISLANDS) LTD. STOCK INCENTIVE PLAN (as restated on November 5, 2003)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00061-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00061-of-00352.parquet"}]]